EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study

Jee Soo Park, Soo Beom Choi, Won Sik Jang, Jongchan Kim, Won Sik Ham

European Urology Focus · 2024-03 · 10 (2) · 306-314

DOI: 10.1016/j.euf.2024.02.002 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Urology Focus, 2024-03. Verfasst von Jee Soo Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Urology, Sorok…. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Dementia, Adrenergic beta-3 Receptor Agonists, Drug Therapy, Combination. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Korean Neurological Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: An overactive bladder (OAB) is primarily managed with behavioural therapy and using anticholinergics and beta-3 agonists. Reports have shown that the use of anticholinergics by OAB patients was associated with an increased risk of new-onset dementia compared with those using beta-3 agonists. This study compares the risks of dementia among patients with an OAB starting on a beta-3 agonist alone, an anticholinergic alone, or a combination treatment. METHODS: Using data from the Korean National Health Insurance Service database, we studied a nationwide population cohort comprising patients newly diagnosed with an OAB who initiated their OAB medications between 2015 and 2020. The treatment types were categorised as anticholinergics (oxybutynin, solifenacin, tolterodine, trospium, fesoterodine, flavoxate, and propiverine) alone, a beta-3 agonist (mirabegron) alone, and combination therapy (an anticholinergic plus the beta-3 agonist). To evaluate the impact of cumulative drug exposure, we quantified the cumulative exposure to solifenacin and mirabegron as cumulative defined daily doses (cDDDs) using proportional hazards regression analyses, adjusted for factors known to be associated with dementia. KEY FINDINGS AND LIMITATIONS: Among the study's 3 452 705 patients, 671 974 were new users of a beta-3 agonist alone (19.5%), 1 943 414 new users of anticholinergics alone (56.3%), and 837 317 receiving combination therapy (24.3%). The most common anticholinergic used both alone and as part of a combination treatment was solifenacin (42.9% and 56.3%, respectively). There was an increased risk of dementia between the users of an anticholinergic alone (adjusted hazard ratio [aHR] = 1.213; 95% confidence interval [CI], 1.195-1.232) and those taking a combination treatment (aHR = 1.345; 95% CI, 1.323-1.366) compared with the users of beta-3 agonists alone after the adjustment of covariates. However, the incidence of dementia was also significantly higher, with an increase in the cumulative dose of mirabegron (aHR = 1.062 [1.021-1.106] for 28-120 cDDDs and aHR = 1.044 [1.004-1.084)] for patients who received >121 cDDDs compared with those who received

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveDementiaAdrenergic beta-3 Receptor AgonistsDrug Therapy, CombinationCholinergic AntagonistsHumansFemaleMaleAgedRepublic of KoreaMiddle AgedCohort StudiesAdultAged, 80 and overRisk AssessmentAcetanilidesThiazoles

Stichwörter der Autor:innen

AnticholinergicsBeta-3 agonistDementiaOveractive bladder

Substanzen

Adrenergic beta-3 Receptor AgonistsCholinergic AntagonistsmirabegronAcetanilidesThiazoles

Autor:innen und Institutionen

  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Urology, Sorokdo National Hospital, Goheung, Republic of Korea; Incheon Airport Nati…
  • Division of Urban Society Research, Seoul Institute, Seoul, Republic of Korea. Electronic address: plains7@si.re.kr.
  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: sindakjang@yuhs.ac.
  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Urology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republi…
  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: uroham@yuhs.ac.

Förderung

  • Korean Neurological Association

Zitieren

APA

Park, J. S., Choi, S. B., Jang, W. S., Kim, J., & Ham, W. S. (2024). Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study. European Urology Focus, 10(2), 306-314. https://doi.org/10.1016/j.euf.2024.02.002

Vancouver

Park JS, Choi SB, Jang WS, Kim J, Ham WS. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study. European Urology Focus. 2024;10(2):306-314. doi:10.1016/j.euf.2024.02.002

BibTeX
@article{Park2024,
  author = {Park, Jee Soo and Choi, Soo Beom and Jang, Won Sik and Kim, Jongchan and Ham, Won Sik},
  title = {Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study},
  journal = {European Urology Focus},
  year = {2024},
  volume = {10},
  number = {2},
  pages = {306--314},
  doi = {10.1016/j.euf.2024.02.002}
}
Kostenlos starten →